UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934


Date of Report (Date of earliest event reported)     July 12, 2006
                                                --------------------------------


                              NEOPROBE CORPORATION
--------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

          Delaware                  0-26520          31-1080091
--------------------------------------------------------------------------------
(State or other jurisdiction      (Commission      (IRS Employer
      of incorporation)           File Number)   Identification No.)

425 Metro Place North, Suite 300, Columbus, Ohio        43017
    (Address of principal executive offices)         (Zip Code)

Registrant's telephone number, including area code     (614) 793-7500
                                                  ------------------------------

         (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)

[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))

[] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))


<PAGE>

ITEM 8.01. OTHER EVENTS.

      On July 12, 2006, Neoprobe Corporation (the "Company") announced that it
had initiated its Phase 2 multi-center study of Lymphoseek(TM), a lymphatic
tissue targeting agent being developed by the Company. The Company was granted
authorization by the FDA earlier this year to commence patient enrollment in a
Phase 2 multi-center clinical study to evaluate the safety and efficacy of
Lymphoseek. The Company issued a press release on July 12, 2006, announcing the
initiation of the Phase 2 clinical study. A copy of the press release is
attached hereto as Exhibit 99.1 and is incorporated herein by reference.

      Statements contained or incorporated by reference in this Current Report
on Form 8-K which relate to other than strictly historical facts, such as
statements about the Company's plans and strategies, expectations for future
financial performance, new and existing products and technologies, anticipated
clinical and regulatory pathways, and markets for the Company's products are
forward-looking statements. The words "believe," "expect," "anticipate,"
"estimate," "project," and similar expressions identify forward-looking
statements that speak only as of the date hereof. Investors are cautioned that
such statements involve risks and uncertainties that could cause actual results
to differ materially from historical or anticipated results due to many factors
including, but not limited to, the Company's continuing operating losses,
uncertainty of market acceptance of its products, reliance on third party
manufacturers, accumulated deficit, future capital needs, uncertainty of capital
funding, dependence on limited product line and distribution channels,
competition, limited marketing and manufacturing experience, risks of
development of new products, regulatory risks and other risks detailed in the
Company's most recent Annual Report on Form 10-KSB and other Securities and
Exchange Commission filings. The Company undertakes no obligation to publicly
update or revise any forward-looking statements.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits.


Exhibit
Number            Exhibit Description

99.1              Neoprobe Corporation press release dated July 12, 2006,
                  entitled "Neoprobe Initiates Lymphoseek Phase 2 Clinical
                  Study."


                                       2
<PAGE>

                                   SIGNATURES


      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                              Neoprobe Corporation


Date: July 14, 2006           By:  /s/ Brent L. Larson
                                   --------------------------------------------
                                   Brent L. Larson, Vice President, Finance and
                                   Chief Financial Officer






                                       3
{"company-data": {"conformed-name": "NEOPROBE CORP", "cik": "0000810509", "assigned-sic": "3841", "irs-number": "311080091", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-26520", "film-number": "06962776"}, "business-address": {"street1": "425 METRO PLACE N", "street2": "STE 400", "city": "DUBLIN", "state": "OH", "zip": "43017", "phone": "6147937500"}, "mail-address": {"street1": "425 METRO PLACE NORTH", "street2": "SUITE 400", "city": "DUBLIN", "state": "OH", "zip": "43017"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported)     July 12, 2006
                                                --------------------------------

                              NEOPROBE CORPORATION
--------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

          Delaware                  0-26520          31-1080091
--------------------------------------------------------------------------------
(State or other jurisdiction      (Commission      (IRS Employer
      of incorporation)           File Number)   Identification No.)

425 Metro Place North, Suite 300, Columbus, Ohio        43017
    (Address of principal executive offices)         (Zip Code)

Registrant's telephone number, including area code     (614) 793-7500
                                                  ------------------------------

         (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)

[] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)

[] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))

[] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
ITEM 8.01. OTHER EVENTS.

      On July 12, 2006, Neoprobe Corporation (the "Company") announced that it
had initiated its Phase 2 multi-center study of Lymphoseek(TM), a lymphatic
tissue targeting agent being developed by the Company. The Company was granted
authorization by the FDA earlier this year to commence patient enrollment in a
Phase 2 multi-center clinical study to evaluate the safety and efficacy of
Lymphoseek. The Company issued a press release on July 12, 2006, announcing the
initiation of the Phase 2 clinical study. A copy of the press release is
attached hereto as Exhibit 99.1 and is incorporated herein by reference.

      Statements contained or incorporated by reference in this Current Report
on Form 8-K which relate to other than strictly historical facts, such as
statements about the Company's plans and strategies, expectations for future
financial performance, new and existing products and technologies, anticipated
clinical and regulatory pathways, and markets for the Company's products are
forward-looking statements. The words "believe," "expect," "anticipate,"
"estimate," "project," and similar expressions identify forward-looking
statements that speak only as of the date hereof. Investors are cautioned that
such statements involve risks and uncertainties that could cause actual results
to differ materially from historical or anticipated results due to many factors
including, but not limited to, the Company's continuing operating losses,
uncertainty of market acceptance of its products, reliance on third party
manufacturers, accumulated deficit, future capital needs, uncertainty of capital
funding, dependence on limited product line and distribution channels,
competition, limited marketing and manufacturing experience, risks of
development of new products, regulatory risks and other risks detailed in the
Company's most recent Annual Report on Form 10-KSB and other Securities and
Exchange Commission filings. The Company undertakes no obligation to publicly
update or revise any forward-looking statements.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits.

Exhibit
Number            Exhibit Description

99.1              Neoprobe Corporation press release dated July 12, 2006,
                  entitled "Neoprobe Initiates Lymphoseek Phase 2 Clinical
                  Study."

                                       2
SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                              Neoprobe Corporation

Date: July 14, 2006           By:  /s/ Brent L. Larson
                                   --------------------------------------------
                                   Brent L. Larson, Vice President, Finance and
                                   Chief Financial Officer

                                       3